Releases
23. September, 2022
Successful outcome of pharmacokinetic trial in children of lead candidate
Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001...
Releases
5. September, 2022
First patient dosed in pivotal trial of lead product candidate
First patient has been dosed in pivotal trial of lead candidate CT001 The pivotal...
Releases
19. August, 2022
Second quarter report Q2-2022
Cessatech A/S today releases its results for the period 1 April – 30 June...
Releases
30. June, 2022
Regulatory Green Light for trial 0205, the pivotal trial for CT001 – first patient expected shortly
Cessatech A/S announces that the pivotal trial 0205 has obtained regulatory approval and thereby...
Releases
16. May, 2022
Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate
Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing...
Releases
19. April, 2022
First quarter report Q1-2022
Cessatech A/S today releases its results for the period 1 January – 31 March...
Releases
8. March, 2022
Successful outcome from trial 0204
Cessatech reports successful outcome of bioavailability trial 0204 Topline results of clinical trial 0204...
Releases
3. March, 2022
Annual report 2021 published
Cessatech A/S publishes its annual report for the fiscal year 2021. “We managed to...
Releases
6. January, 2022
Changes to the Board of Directors – welcome to Rachel
Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with...
Releases
22. December, 2021
Cessatech successfully raises DKK 24.3 million through warrant exercise
During the period 25 November – 16 December 2021, holders of TO 1 have...
Releases
25. November, 2021
Exercise warrants of series TO1 before 14 Dec
In connection with the Company’s IPO in November/December 2020, Cessatech issued units (shares and...
Releases
2. November, 2021
First US patent covering CT001
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799...
Want to see all releases?
To see all releases including those not listed here, go to our filings and reports.